Systems and methods for treating patients with processed lipoaspirate cells
View Patent ↗Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.
1. A self contained adipose-derived stem cell processing unit, comprising:
a tissue collection container that is configured to receive unprocessed adipose tissue that is removed from a patient, wherein said tissue collection container is defined by a closed system;
a first filter that is disposed within said tissue collection container, wherein said first filter is configured to substantially retain a first component of said unprocessed adipose tissue and pass a second component of said unprocessed adipose tissue, such that said first filter substantially separates said first component from said second component, and wherein said first component comprises a cell population that comprises adipose-derived stem cells and said second component comprises mature adipocytes;
a cell collection container, which is configured to receive said first component comprising a cell population that comprises adipose-derived stem cells from said tissue collection container, wherein said cell collection container is within said closed system;
a conduit configured to allow passage of said first component comprising a cell population comprising adipose-derived stem cells from said tissue collection container to said cell collection container while maintaining a closed system; and
a cell concentrator disposed within said cell collection container that is configured to facilitate the concentration of said first component comprising a cell population that comprises adipose-derived stem cells, wherein said cell concentrator comprises a centrifuge or a spinning membrane filter.
2. A method of using the self -contained adipose-derived stem cell processing unit of claim 1 to process a cell population that comprises adipose-derived stem cells, comprising:
removing adipose tissue that comprises a cell population that comprises adipose-derived stem cells from said patient;
introducing the removed adipose tissue that comprises said cell population that comprises adipose-derived stem cells into the adipose-derived stem cell processing unit of claim 1 ; and
separating and concentrating said cell population that comprises adipose-derived stem cells from said removed adipose tissue within said self-contained adipose-derived stem cell processing unit while maintaining said closed pathway to obtain a concentrated cell population that comprises adipose-derived stem cells.
3. The method of claim 2 , further comprising contacting said cell population that comprises adipose-derived stem cells with an additive.
4. The method of claim 2 , further comprising mixing said concentrated cell population that comprises adipose-derived stem cells with a second portion of unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments from said patient.
5. The method of claim 2 , further comprising cooling said concentrated cell population that comprises adipose-derived stem cells.
6. The method of claim 2 , wherein said first portion of adipose tissue that is removed from said patient is lipoaspirate.
7. The method of claim 2 , wherein said first portion of adipose tissue that is removed from said patient is obtained by excisional lipectomy.
8. The method of claim 4 , wherein said second portion of adipose tissue that is removed from said patient is lipoaspirate.
9. The method of claim 4 , wherein said second portion of adipose tissue that is removed from said patient is obtained by excisional lipectomy.
10. The method of claim 3 , wherein said additive is a tissue or tissue fragment.
11. The method of claim 3 , wherein said additive is demineralized bone.
12. The method of claim 3 , wherein said additive is a compound of the thiaglitazone family.
13. The method of claim 3 , wherein said additive is insulin.
14. The method of claim 3 , wherein said additive is an exogenous DNA.
15. The method of claim 3 , wherein said additive is a biological or artificial scaffold.
16. The method of claim 15 , wherein said biological or artificial scaffold is a resorbable plastic sheath.
17. The method of claim 3 , wherein said additive is an immunosuppressive agent.
18. The method of claim 17 , wherein said immunosuppressive agent is selected from the group consisting of cyclosporine, myophenylate mofetil, rapamycin, and antithymocyte globulin.
19. The method of claim 3 , wherein said additive is a cell differentiation agent.
20. The method of claim 19 , wherein said cell differentiation agent is a cytokine.
21. The method of claim 19 , wherein said cell differentiation agent is a growth factor.
22. The method of claim 3 , wherein said additive is an antimicrobial agent.
23. The method of claim 2 , further comprising mechanically or enzymatically disaggregating said removed adipose tissue that comprises said cell population that comprises adipose-derived stem cells.
24. The method of claim 2 , wherein said cell population comprising said adipose-derived stem cells is separated from mature adipocytes and connective tissue present in adipose tissue that was removed from said patient by employing a filter.
25. The adipose-derived stem cell processing unit of claim 1 , wherein said cell concentrator comprises a spinning membrane filter.
26. The adipose-derived stem cell processing unit of claim 1 , wherein said cell concentrator comprises an antibody.
27. The adipose-derived stem cell processing unit of claim 26 , wherein said antibody is selected from the group consisting of AP2, CD3, CD19, and CD11 b.
28. The adipose-derived stem cell processing unit of claim 1 , wherein said cell concentrator comprises a centrifuge.
29. The method of claim 23 , wherein the removed adipose tissue that comprises said cell population that comprises adipose-derived stem cells is enzymatically digested.
30. The method of claim 29 , wherein said enzymatic digestion comprises a collagenase.
31. The method of claim 29 , wherein said enzymatic digestion comprises a neutral protease.
32. The method of claim 29 , wherein said enzymatic digestion comprises trypsin.
33. The method of claim 2 , wherein said concentrated cell population that comprises adipose-derived stem cells comprises endothelial precursor cells.
34. The method of claim 5 , wherein said cooling of said concentrated cell population that comprises adipose-derived stem cells is performed within said self-contained adipose-derived stem cell processing unit while maintaining a closed pathway.
35. The method of claim 5 , wherein said concentrated cell population that comprises adipose-derived stem cells is cryopreserved.
36. The method of claim 3 , wherein said additive is unprocessed adipose tissue that comprises intact, non-disaggregated tissue fragments.
37. The adipose-derived stem cell processing unit of claim 1 , further comprising a temperature control device.
38. The adipose-derived stem cell processing unit of claim 37 , wherein the temperature control device is configured to adjust the temperature of the components in the tissue collection container.
39. The adipose-derived stem cell processing unit of claim 37 , wherein the temperature control device is configured to adjust the temperature of fluid that is delivered to the tissue collection container.
40. The adipose-derived stem cell processing unit of claim 1 , further comprising a microprocessor configured to automate the self-contained adipose-derived stem cell processing unit.
41. The adipose-derived stem cell processing unit of claim 40 , further comprising a temperature control device.
42. The self contained adipose-derived stem cell processing unit of claim 1 , comprising an aspiration port coupled to a suction device.
43. The self contained adipose-derived stem cell processing unit of claim 1 , wherein said second component comprises lipid.
44. The self contained adipose-derived stem cell processing unit of claim 1 , wherein said second component comprises blood.
45. The self contained adipose-derived stem cell processing unit of claim 1 , further comprising an outlet configured to allow the aseptic removal of said concentrated population of cells that comprises adipose-derived stem cells.